jpad journal

AND option

OR option

Editorial board


Jacques Touchon (Montpellier, France)
Bruno Vellas (Toulouse, France)
Paul Aisen (San Diego, USA)

Sections and Associate Editors

Methodological Aspects of Preventive Trials: Sandrine Andrieu (Toulouse, France)
Operational Aspects of Preventive Trials: Bruno Vellas (Toulouse, France) 
Health Economic and Finances Aspects: Ara Khachaturian (Washington, USA)
Health Policy, Regulations: Zaven Khachaturian (Potomac, USA)
Bioinformatics Analytics: Ron Thomas (San Diego, USA)
Intervention Pharmacological: Paul Aisen (San Diego, USA)
Non Pharmacological: Eric Larson (Seattle, USA)
Health Promotion: Mia Kivipelto (Stockholm, Sweden)
Ethics : Jason Karlawish (Philadelphia, USA)
Imaging and Biomarkers: Mike Weiner (San Francisco, USA)
Pre-Clinical Study: Natalio Vita (Toulouse, France)
Diabetes and Cognitive Decline: Alan Sinclair (Bedfordshire, United Kingdom)

Editorial Board

K.J. Anstey (The Australian National University, Canberra, Australia)
R. Bateman (Washington University School of Medicine, Saint Louis, USA)
D. Bennett (Rush University Medical Center, Chicago, USA)
H.R. Brashear (JNJ, Alzheimer’s Immunotherapy R&D, San Francisco, USA)
C. Brayne (University of Cambridge, Cambridge, United Kingdom)
J. Breitner (McGill Center for Studies in Aging, Montreal, Canada)
M. Carrillo (Alzheimer’s Association, Chicago, USA)
J.M. Cedarbaum (Biogen Iden, Woodbridge, USA)
J. Cummings (Cleveland Clinic Lou Ruvo Center for Brain, Las Vegas, USA)
R.S. Doody (Baylor College of Medicine, Houston, USA)
B. Dubois (Institut de la Mémoire et de la Maladie d’Alzheimer, Paris, France)
H. Feldman (University of Vancouver, Vancouver, Canada)
L. Feng (Singapore)
H. Fillit (Alzheimer’s Drug Discovery Foundation , New York, USA)
G. Frisoni (IRCCS San Giovanni Dio, Brescia, Italy)
J. George (Alzheimer Europe, Luxembourg)
D. Gustafson (State University of New York, New York, USA)
M. Grundman (Global R&D Partners, LLC, San Diego, USA)
H.J. Hampel (Ludwig-Maximilian University, Munich, Germany)
M. Isaac (European Medicines Agency, London, United Kingdom)
F. Jessen (Rheinische- Friedrich-Wilhelms-Universität, Bonn, Germany)
T. Kwok (The Chinese University of Hong Kong, Shalin, Hong Kong)
Y. Lee (Ajou University School of Medicine, Suwon, Republic of Korea)
V. Legrand (ICON Clinical Research, Sèvres, France)
J.A. Luchsinger (Columbia University, New York, USA)
M. Morris (Rush Institute, Chicago, USA)
R. Petersen (Mayo Clinic, Rochester, USA)
E. Reiman (Banner Alzheimer’s Institute, Phoenix, USA)
E. Richard (University of Amsterdam, Amsterdam, The Netherlands)
C. Ritchie (Imperial College of London, London, United Kingdom)
S. Salloway (The Warren Alpert Medical School of Brown University, Providence, USA)
C. Scerri (University of Malta, Msida, Malta)
P. Scheltens (Alzheimer Center VUmc, Amsterdam, The Netherlands)
R. Schindler (Pfizer, Inc., New York, USA)
F.A. Schmitt  (University of Kentucky, Lexington, USA)
E. Siemers (Lilly Corporate Center, Indianapolis, USA)
D. Smith (University Department of Pharmacology, Oxford, United Kingdom)
R. Sperling (Brigham and Women’s Hospital, Boston, USA)
P. Tariot (Banner Alzheimer’s Institute, Phoenix, USA)
C. van Dyck (Yale University School of Medicine, New Haven, USA)
S. Villeneuve (McGill University, Montréal, Canada)
P. Wang (University of Yang-Ming, Beijing, China)
P. Whitehouse (Case Western Reserve University, Shaker Heights, USA)
K. Yaffe (University of California, San Francisco, USA)
J.-T. Yu (Qingdao, China)